

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 44

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

PC 07120
Licensee

318427

<p>1. LaPorte Hospital and Health Services Department of Nuclear Medicine</p> <p>2. 1007 Lincolnway LaPorte, IN 46350-0250</p>	<p>In accordance with letter dated August 12, 2009,</p> <p>3. License number 13-15151-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date March 31, 2014</p> <hr/> <p>5. Docket No. 030-08653 Reference No.</p>
--	--

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 5 curies
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed sources (Bard Brachytherapy, Inc. Model No. STM 1251 and Theragenics Corp. Model No. 200 and I-seed Model 125.S06)	D. 2 curies
E. Any byproduct material permitted by 10 CFR 35.500	E. Sealed sources identified in 10 CFR 35.500 (North American Scientific Model No. MED 3601 or DuPont Pharma Model No. NES 8412 and Isotope Products Model HEG-137)	E. 400 millicuries
F. Depleted uranium	F. Stainless steel covered metal	F. 4 shields, not to exceed 12 kilograms each

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-15151-01

Docket or Reference Number
030-08653

Amendment No. 44

- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.
- F. Shielding in ADAC Laboratories MCD-AC attenuation correction system.

CONDITIONS

- 10. Licensed material may be used at the licensee's facilities located at 1007 Lincolnway, LaPorte, Indiana.
- 11. Radiation Safety Officer: James C. Hatten.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Hester Muller, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Smari Thordarson, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Douglas J. Van Putten, M.D.	10 CFR 35.400.
John E. DePersio, M.D.	10 CFR 35.100, 35.200, and 35.300 (for iodine-131, oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries).
Vivek Mishra, M.D.	10 CFR 35.100 and 35.200.
Richard Dobben, M.D.	10 CFR 35.100, 35.200, iodine-131 for use under 35.300 and 35.500.
Chester Wilson, M.D.	10 CFR 35.400
Krishna R. Pillai, M.D.	10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-15151-01Docket or Reference Number
030-08653

Amendment No. 44

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application received March 5, 2004;
 - B. Letters dated June 9, 2005, October 14, 2005, November 1, 2006 and December 27, 2006;
 - C. Facsimile letters dated September 6, 2005, September 8, 2005; and
 - D. Facsimile (of e-mail) received February 15, 2007.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date SEP 09 2009By 
James R. Mullauer, M.H.S.
Materials Licensing Branch
Region III